Vaccine against IBR and Infectious Keratoconjunctivitis.
Optimal immune response against eye diseases. The MBS molecular verification of the genes of interest (gB gene) applied in Visualmix is key to producing the main immunogenic glycoproteins in IBR, responsible for the generation of neutralizing antibodies.
Dose
3 ml.
Administration
Primary vaccinations: from 3 months of age, 2 doses 21 days apart. Primarily vaccinated pregnant females: 2 doses 21 days apart. Revaccinate semi-annually.
Content
Bottle containing 240 ml / 80 doses or 90 ml / 30 doses
Composition
Inactivated cultures of HVB type I and Moraxella bovis. Adjuvant: aluminum gel.
